Sharemaestro company-news research for Sanofi (SAN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
PAR
France
Measured evidence
Company news sentiment
SAN news sentiment
Sanofi
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone55Neutral is 50
Balanced news tone
72/100 evidence confidence
100% direct company focus
6 current stories across 1 publishers
Current company news
Balanced read
Balanced news tone is drawn from 6 fresh independent stories, including 6 company-specific items across 1 publishers.
Latest source headline [Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) finance.yahoo.com · 12 Aug 2026 17:30What supports the read
6 current stories are mapped specifically to SAN.
Cross-story agreement is 89/100, indicating a comparatively coherent tape.
What tempers the read
Only 1 publisher currently contribute to the measured read.
55/100
Weighted toneBalanced news tone
72/100
Evidence confidencesolid confidence
100%/100
Company focus6 direct stories
89/100
Evidence agreement11/100 dispersion
News history
Tone and story flow over 21 days
23 Jul02 Aug12 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth69
5.49 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness80
recency-weighted evidenceAgreement89
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
News tone and price action are not far from neutral.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Regulatory and legal592 stories · 33%
Earnings241 stories · 17%
Market update651 stories · 17%
Guidance611 stories · 17%
Analyst action611 stories · 17%
Source mix
Where the evidence comes from
finance.yahoo.com576 stories · 100%
Recurring subjects
Subjects appearing most often
Clinical Trials4Biotech3Partnerships2Earnings2Sports Nutrition1Share Price1Pharma1Oncology1Net Income1Market Research Reports1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#161Tone
finance.yahoo.comDirect company coverage
[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach around USD 26.04 Billion by 2034, at a CAGR of 7.56% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, Alpavit, Arla Foods, Carbery Group, Davisco Foods International, Inc., Fonterra Co-operative Group Lt
Dietary SupplementsE CommerceFunctional FoodsGrowth RateMarket Research ReportsSports Nutrition
- Published
- 12 Aug 2026 17:30
- Catalyst
- Guidance
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#265Tone
finance.yahoo.comDirect company coverage
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001
IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro
Antibody Drug ConjugatesBiotechCancerClinical Trials
- Published
- 12 Aug 2026 11:30
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#354Tone
finance.yahoo.comDirect company coverage
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Adagene Inc. Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established Data reported at AACR from triple combination therapy in 1L hepatocellular carcinoma (HCC) and late-line MSS CRC highlights muzastotug's potential as a backbone combination treatment for multiple tumor types across all lines of therapy Initiated dosing in a global Phase 1/2 basket trial evaluating muzastotug in combination with a next-generation investigational IO ag
BiotechClinical TrialsFinancial ResultsOncologyPartnerships
- Published
- 12 Aug 2026 11:30
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#463Tone
finance.yahoo.comDirect company coverage
Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine
It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline review under CEO Belén Garijo, who chose to pull the plug after efficacy and safety data failed to support global regulatory submissions. For a mega-cap pharmaceutical giant like Sanofi, valued at more than $100 billion, abandoning a zero-revenue clinical trial asset is a neces
BiotechClinical TrialsEarningsEarnings ReportFda ApprovalInstitutional Investors
- Published
- 10 Aug 2026 23:29
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#561Tone
finance.yahoo.comDirect company coverage
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after advancing into clinical development under its collaboration with Sanofi (SNY), RBC Capital Markets said in a Monday research note.The investment firm said limited preclinical data Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now
Clinical TrialsPharma
- Published
- 10 Aug 2026 16:44
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#624Tone
finance.yahoo.comDirect company coverage
Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed
In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside the weak year-on-year comparisons, Novavax beat analyst expectations for both revenue and earnings and highlighted progress on high-profile partnerships, including Sanofi and Pfizer, while also filing an US$82.47 million employee stock offering shelf registration. Now we'll examine how this mix of better-than-expected Q2 resul
Dilution RiskEarningsGuidanceNet IncomePartnershipsShare Price
- Published
- 08 Aug 2026 10:10
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.